ABCELLERA BIOLOGICS (8QQ) — Financial Flexibility Index
ABCELLERA BIOLOGICS (8QQ) has a Financial Flexibility Index of -0.06x as of December 2025. Free cash flow of €-24.90 Million (operating CF €-34.74 Million minus capex €9.84 Million) represents 0% of total liabilities (€390.05 Million). Also explore 8QQ net asset momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
ABCELLERA BIOLOGICS Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for ABCELLERA BIOLOGICS across 5 annual periods. Check asset allocation strategy of ABCELLERA BIOLOGICS to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for ABCELLERA BIOLOGICS (2021–2025)
Year-by-year free cash flow to debt coverage for ABCELLERA BIOLOGICS. For the full company profile including market capitalisation, see ABCELLERA BIOLOGICS (8QQ) total market value.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.23x | €-88.52 Million | €-131.29 Million | €390.05 Million | ▼ -129.1% |
| 2024 | -0.10x | €-30.16 Million | €-108.56 Million | €304.47 Million | ▼ -198.9% |
| 2023 | 0.10x | €33.63 Million | €-43.88 Million | €335.78 Million | ▼ -91.2% |
| 2022 | 1.14x | €350.02 Million | €277.36 Million | €307.63 Million | ▲ +9.9% |
| 2021 | 1.03x | €303.04 Million | €244.58 Million | €292.84 Million | — |